Antioxidants and Redox Signaling, volume 41, issue 16-18, pages 1031-1050
A core NRF2 gene set defined through comprehensive transcriptomic analysis predicts selective drug resistance and poor multi-cancer prognosis
George Luo
1
,
Harshita Kumar
2, 3
,
Kristin Alridge
4
,
Kristin Aldridge
5
,
Stevie Rieger
4, 6
,
Eunhyang Han
1, 7
,
Ethan Jiang
8, 9
,
Ernest Chan
10
,
Ernest R Chan
11
,
Ahmed Soliman
12, 13
,
Haider Mahdi
14, 15, 16, 17
,
John J. Letterio
18, 19, 20, 21
1
5
Triterpenoid Therapeutics Inc., Tunbridge, Vermont, USA.
|
12
SUNY Downstate Medical Center, Pediatrics, New York City, New York, United States;
|
13
Department of Pediatrics, SUNY Downstate Hospital, Brooklyn, New York, USA.
16
19
The Angie Fowler Adolescent and Young Adult Cancer Institute, University Hospitals Rainbow Babies & Children’s Hospital, Cleveland, Ohio, USA.
20
The Case Comprehensive Cancer Center, Cleveland, Ohio, USA.
Publication type: Journal Article
Publication date: 2024-12-01
Journal:
Antioxidants and Redox Signaling
scimago Q1
SJR: 1.708
CiteScore: 14.1
Impact factor: 5.9
ISSN: 15230864, 15577716
PubMed ID:
39028025
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.